{"id":329515,"date":"2006-07-11T08:55:00","date_gmt":"2006-07-11T13:55:00","guid":{"rendered":"https:\/\/www.investmentexecutive.com\/uncategorized\/news-34731\/"},"modified":"2019-10-30T05:56:15","modified_gmt":"2019-10-30T09:56:15","slug":"news-34731","status":"publish","type":"post","link":"https:\/\/www.investmentexecutive.com\/newspaper_\/focus-on-products\/news-34731\/","title":{"rendered":"Empire Life tweaks Solution Series"},"content":{"rendered":"<p>Kingston, Ont.-based Empire Life Insurance Co. is changing its Solution Series term life insurance products, including a new pricing band and a \u201cno fluids\u201d approach to underwriting policies. The \u201cno fluids\u201d clause in policies up to $249,999 and age 45 will be extended to all life insurance products offered by Empire. (Previously, a saliva or urine HIV test was required to issue a term policy of certain face amounts; the test was conducted by either the client\u2019s advisor or a paramedical nurse.) \u201cThis change reflects the emerging standard in the term marketplace and extends it to other life products,\u201d says Owen Rhoden, manager of individual life and health insurance marketing for Empire. \u201cWe want to do what makes sense for our distribution partners and their clients.\u201d Empire has also added a new pricing band from $250,000 to $499,999 to provide consumers with more options, the company says. A first-year commission increase of 5% will be added to Solution 10 and Solution 20 products until Sept. 29.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kingston, Ont.-based Empire Life Insurance Co. is changing its Solution Series term life insurance products, including a new pricing band and a \u201cno fluids\u201d approach to underwriting policies. The \u201cno fluids\u201d clause in policies up to $249,999 and age 45 will be extended to all life insurance products offered by Empire. (Previously, a saliva or [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3013,3017],"tags":[],"yst_prominent_words":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/posts\/329515"}],"collection":[{"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/comments?post=329515"}],"version-history":[{"count":2,"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/posts\/329515\/revisions"}],"predecessor-version":[{"id":369411,"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/posts\/329515\/revisions\/369411"}],"wp:attachment":[{"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/media?parent=329515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/categories?post=329515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/tags?post=329515"},{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/www.investmentexecutive.com\/wp-json\/wp\/v2\/yst_prominent_words?post=329515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}